MEDLIVE TECHNOLOGY CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.46 HKD | -0.94% |
|
-3.20% | -0.24% |
| Apr. 29 | Medlive Technology More than Doubles Profit in 2023 | MT |
| Mar. 25 | Medlive Technology Co., Ltd. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on June 24, 2024 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 15,807 | 5,404 | 5,603 | 5,687 | - | - |
| Enterprise Value (EV) 1 | 11,941 | 1,228 | 5,603 | 1,344 | 1,276 | 1,197 |
| P/E ratio | 347 x | 47.3 x | 23.4 x | 27.6 x | 29 x | 26.7 x |
| Yield | 0.08% | 0.87% | - | 1.83% | 2.08% | 2.08% |
| Capitalization / Revenue | 55.6 x | 17.2 x | 13.6 x | 11 x | 8.92 x | 7.35 x |
| EV / Revenue | 42 x | 3.91 x | 13.6 x | 2.6 x | 2 x | 1.55 x |
| EV / EBITDA | 156 x | 17.4 x | 67.1 x | 12.3 x | 9.24 x | 6.93 x |
| EV / FCF | - | - | - | 17.2 x | 10.5 x | 8.68 x |
| FCF Yield | - | - | - | 5.81% | 9.54% | 11.5% |
| Price to Book | 3.57 x | - | - | 1.16 x | 1.07 x | 0.99 x |
| Nbr of stocks (in thousands) | 713,226 | 717,348 | 726,963 | 726,962 | - | - |
| Reference price 2 | 22.16 | 7.534 | 7.708 | 7.823 | 7.823 | 7.823 |
| Announcement Date | 3/24/22 | 3/23/23 | 3/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 284.4 | 314.1 | 412 | 516.8 | 637.3 | 774.1 |
| EBITDA 1 | - | 76.61 | 70.39 | 83.45 | 109.3 | 138 | 172.6 |
| EBIT 1 | - | 73.07 | 61.4 | 74.08 | 93.41 | 123.8 | 157 |
| Operating Margin | - | 25.69% | 19.55% | 17.98% | 18.08% | 19.43% | 20.29% |
| Earnings before Tax (EBT) 1 | - | 69.93 | 135 | 253.1 | 276.8 | 241.2 | 272.3 |
| Net income 1 | 85.2 | 40.62 | 117.3 | 242.3 | 240.4 | 210.9 | 238.6 |
| Net margin | - | 14.28% | 37.36% | 58.81% | 46.52% | 33.1% | 30.82% |
| EPS 2 | 0.1592 | 0.0639 | 0.1593 | 0.3299 | 0.2838 | 0.2694 | 0.2929 |
| Free Cash Flow 1 | - | - | - | - | 78.12 | 121.7 | 137.9 |
| FCF margin | - | - | - | - | 15.12% | 19.1% | 17.81% |
| FCF Conversion (EBITDA) | - | - | - | - | 71.45% | 88.17% | 79.88% |
| FCF Conversion (Net income) | - | - | - | - | 32.5% | 57.7% | 57.8% |
| Dividend per Share 2 | - | 0.0170 | 0.0654 | - | 0.1434 | 0.1624 | 0.1630 |
| Announcement Date | 6/29/21 | 3/24/22 | 3/23/23 | 3/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 130.7 | 153.8 | 132 | 182.1 | 173.5 | - | 209.3 | 273.3 |
| EBITDA 1 | - | - | - | - | - | - | 66.52 | 67.79 |
| EBIT 1 | 34.93 | 38.14 | 24.14 | 37.26 | 31.8 | - | 45.22 | 49.7 |
| Operating Margin | 26.73% | 24.8% | 18.29% | 20.46% | 18.33% | - | 21.61% | 18.18% |
| Earnings before Tax (EBT) 1 | - | - | - | - | - | - | 136.4 | 140.3 |
| Net income 1 | - | - | 26.97 | - | - | - | 113.7 | 117.1 |
| Net margin | - | - | 20.44% | - | - | - | 54.35% | 42.83% |
| EPS 2 | - | 0.0281 | 0.0365 | 0.1228 | 0.1339 | 0.1960 | 0.1500 | 0.1600 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 8/26/21 | 3/24/22 | 8/25/22 | 3/23/23 | 9/21/23 | 3/25/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 3,866 | 4,176 | - | 4,343 | 4,411 | 4,490 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | - | 78.1 | 122 | 138 |
| ROE (net income / shareholders' equity) | - | 5.21% | 2.81% | - | 4.5% | 3.96% | 4.13% |
| ROA (Net income/ Total Assets) | - | 1.87% | 2.69% | - | 4.8% | 5.1% | 5.4% |
| Assets 1 | - | 2,172 | 4,359 | - | 5,008 | 4,136 | 4,418 |
| Book Value Per Share 2 | - | 6.210 | - | - | 6.770 | 7.340 | 7.890 |
| Cash Flow per Share 2 | - | 0.0700 | - | - | 0.1000 | 0.1400 | 0.1900 |
| Capex 1 | - | 54.9 | 1.35 | - | 5.77 | 4.47 | 4.96 |
| Capex / Sales | - | 19.3% | 0.43% | - | 1.12% | 0.7% | 0.64% |
| Announcement Date | 6/29/21 | 3/24/22 | 3/23/23 | 3/25/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
7.823
CNY
Average target price
9.314
CNY
Spread / Average Target
+19.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.24% | 787M | |
| +28.69% | 29.12B | |
| +10.76% | 18.76B | |
| +4.75% | 13.23B | |
| -4.56% | 11.76B | |
| +12.30% | 11.35B | |
| +21.10% | 5.06B | |
| -14.65% | 3.65B | |
| +3.71% | 3.52B | |
| +37.85% | 3.51B |
- Stock Market
- Equities
- 2192 Stock
- Financials Medlive Technology Co., Ltd.
